67. 多発性嚢胞腎 Polycystic kidney disease Clinical trials / Disease details
臨床試験数 : 216 / 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-005949-16-NL (EUCTR) | 25/10/2021 | 21/10/2021 | A study into the efficacy and toleratability of leuprorelin by patients suffering from severe polycystic liver disease | A GnRH Agonist IN pre-menopausal women STudy to treat severe Polycystic Liver Disease - AGAINST-PLD | Severe polycystic liver disease in female patients MedDRA version: 20.1;Level: PT;Classification code 10048834;Term: Polycystic liver disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: LLT;Classification code 10036045;Term: Polycystic kidney;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 23.0;Classification code 10083939;Term: Autosomal dominant polycystic liver disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Lucrin Product Name: Lucrin | University Medical Center Groningen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 36 | Phase 2 | Netherlands |